Reginald Seeto - Feb 1, 2023 Form 4 Insider Report for CareDx, Inc. (CDNA)

Signature
/s/ Reginald Seeto
Stock symbol
CDNA
Transactions as of
Feb 1, 2023
Transactions value $
-$253,024
Form type
4
Date filed
2/3/2023, 08:47 PM
Previous filing
Jan 31, 2023
Next filing
Feb 8, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CDNA Common Stock Award $0 +302K +113.04% $0.00 569K Feb 1, 2023 Direct F1, F2
transaction CDNA Common Stock Award $0 +11.8K +2.07% $0.00 581K Feb 1, 2023 Direct F3
transaction CDNA Common Stock Tax liability -$36.5K -2.33K -0.4% $15.66 579K Feb 1, 2023 Direct F4
transaction CDNA Common Stock Sale -$39.5K -2.32K -0.4% $17.07 576K Feb 2, 2023 Direct F5, F6
transaction CDNA Common Stock Sale -$8.8K -503 -0.09% $17.50 576K Feb 2, 2023 Direct F5, F7
transaction CDNA Common Stock Tax liability -$128K -7.24K -1.26% $17.61 569K Feb 2, 2023 Direct F4
transaction CDNA Common Stock Tax liability -$20.3K -1.23K -0.22% $16.54 567K Feb 3, 2023 Direct F4
transaction CDNA Common Stock Tax liability -$20.3K -1.23K -0.22% $16.54 566K Feb 3, 2023 Direct F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CDNA Stock Option (right to buy) Award $0 +156K $0.00 156K Feb 1, 2023 Common Stock 156K $15.66 Direct F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported securities are represented by restricted stock units, 1/4th of which shall vest on February 1, 2024 and 1/4th of which shall vest on each anniversary thereafter.
F2 Includes 177 shares acquired on January 2, 2023 pursuant to the Issuer's 2014 Employee Stock Purchase Plan.
F3 The reported securities were subject to a performance restricted stock unit award that was initially granted on February 3, 2021 for a two-year performance period over calendar years 2021 and 2022, which performance was assessed and finalized effective February 1, 2023. 50.00% of the reported securities vested on February 1, 2023 and 50% of the reported securities will vest on December 31, 2023, subject to the Reporting Person's continued service with the Issuer.
F4 These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units.
F5 This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.40 to $17.34, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased or sold at each separate price.
F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.44 to $17.61, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased or sold at each separate price.
F8 1/4th of the shares subject to the option shall vest on February 2, 2024 and 1/48th of the shares subject to the option shall vest monthly thereafter.

Remarks:

President and Chief Executive Officer